Administrative Core

行政核心

• 批准号: 10017938
• 负责人: JOHN M MARIS
• 金额: $ 9.15万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-18 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10017938
• 关键词: Basic Science; Budgets; Child; Clinical Research; Complex; Development; Disease; Generations; Goals; Infrastructure; Investigation; Lead; Leadership; Mission; Neuroblastoma; Occupational activity of managing finances; Patient-Focused Outcomes; Program Reviews; Records; Reproducibility; Research; Research Personnel; Research Project Grants; Resistance; Structure; Time; Toxic effect; Translational Research; United States National Institutes of Health; assault; design; experience; high risk; improved; improved outcome; multidisciplinary; programs; public health relevance; responsible research conduct; therapy design; therapy resistant

SUMMARY/ABSTRACT Our proposed P01 entitled Discovering and Exploiting Mechanisms of Neuroblastoma (NB) Therapy Resistance is a multi-disciplinary and multi-institutional sustained assault on the unmet need of improving outcomes for children with the high-risk form of the disease. With the ambitious goals articulated in each Project to discover fundamental mechanisms of de novo and acquired therapy resistance to both standard and newly emerging therapies, the Program requires experienced leadership to define priorities, sustain momentum and deliver results that meet defined milestones. Thus, Core A will provide the scientific, budgetary and administrative leadership, as well as the programmatic infrastructure to achieve the translational mission of the proposed investigation. With the guidance of a world-renowned scientific advisory board, Core A will oversee the development of a new generation of rationally designed therapies for children with NB that we expect to ultimately improve cure rates, while simultaneously reducing both short- and long-term toxicities.

摘要/摘要 我们建议的P01题为神经母细胞瘤(NB)治疗的发现和开发机制 抵抗是对未得到满足的改善需求的多学科和多机构的持续攻击 这种疾病的高危形式儿童的结局。每个人都有雄心勃勃的目标 发现对标准和获得性治疗耐药的从头和获得性治疗基本机制的项目 新出现的疗法，该计划需要有经验的领导来确定优先事项，维持 推动并交付符合规定的里程碑的结果。因此，核心A将提供科学的、预算的 和行政领导以及方案基础设施，以实现 拟议中的调查。在世界知名的科学顾问委员会的指导下，Core A将 监督针对NB儿童的新一代合理设计疗法的开发，我们 预计最终将提高治愈率，同时减少短期和长期毒性。